Cautious Optimism for Deal Making. The general consensus is that we will likely see an increase in M&A and capital market transactions in the life sciences sector in 2025....more
1/22/2025
/ Acquisition Agreements ,
Artificial Intelligence ,
Biotechnology ,
Capital Markets ,
Data Protection ,
Healthcare ,
Investment ,
Life Sciences ,
Merger Agreements ,
Pharmaceutical Industry ,
Regulatory Agenda ,
Telehealth
ARTIFICIAL INTELLIGENCE IN LIFE SCIENCES -
Life sciences companies are forming AI-driven strategic collaborations with tech giants, creating synergy that promises to revolutionize the industry. Companies like NVIDIA,...more
8/20/2024
/ Algorithms ,
America Invents Act ,
Artificial Intelligence ,
Bayh-Dole Act ,
Chevron Deference ,
Healthcare ,
Inflation Reduction Act (IRA) ,
Innovative Technology ,
Intellectual Property Protection ,
Life Sciences ,
Machine Learning ,
March-in-Rights ,
NIST ,
Non-Compete Agreements ,
Patents ,
Post-Grant Review ,
Prior Art ,
USPTO
Ballard Spahr attorneys from the firm’s Life Sciences and Health Care Industry Teams were on the ground for the 42nd Annual J.P. Morgan Healthcare Conference (JPM24) from January 7-10. While still less crowded than...more
1/22/2024
/ Acquisitions ,
Antitrust Provisions ,
Coronavirus/COVID-19 ,
Department of Justice (DOJ) ,
Drug Pricing ,
Federal Trade Commission (FTC) ,
Health Care Providers ,
Healthcare ,
Healthcare Reform ,
Initial Public Offering (IPO) ,
Life Sciences ,
Medicare ,
Mergers ,
Pharmaceutical Industry ,
Physicians ,
Prescription Drugs ,
Private Equity
Summary -
In Amgen v. Sanofi, the Supreme Court unanimously affirmed the District of Delaware and Federal Circuit findings that Amgen’s functionally defined patent claims to a class of therapeutic antibodies are invalid as...more